Projektbeschreibung
Einfachere und kostengünstigere Behandlung lebensbedrohlicher Blutgerinnsel
Nierensteine sind zwar schmerzhaft, aber selten lebensbedrohlich. Die Behandlung reicht von der einfachen Zufuhr größerer Flüssigkeitsmengen bis hin zur Operation in schwierigen Fällen. Bei Gerinnseln in körperinneren Venen (tiefe Venenthrombose) reichen diese Maßnahmen aber nicht aus. Große Blutgerinnsel können sich lösen und Lungenarterien blockieren, was häufig tödliche Folgen hat. Meist sind längere Krankenhausaufenthalte und hochwirksame Thrombolytika nötig, letztere jedoch erhöhen wiederum stark das Blutungsrisiko. Das Projekt VETEX bringt eine bahnbrechende neue Therapie auf den Markt, die Blutgerinnsel entfernt und den Einsatz von Thrombolytika reduziert. Damit könnte das Gesundheitswesen entlastet und die Lebensqualität von Millionen Menschen verbessert werden.
Ziel
Deep Vein Thrombosis is the 3rd leading cardiovascular disease behind heart attack and stroke with 1.2M cases diagnosed each year in the EU and US.
Left untreated, one third of DVT patients will be at risk of clot breaking away causing a Pulmonary Embolism which has a 50% mortality rate. In addition, significant chronic complications often occur such as clot recurrence (30%), chronic limb swelling associated with Post Thrombotic Syndrome (50%), ulceration and amputation.
DVT patients are usually treated with drugs. Anticoagulation therapy alone helps prevent clot extension but it does not remove the clot. Other therapies often involve long hospital stays and often require 24-72 hours in ICU due to the significant bleeding risks associated with heavier duty clot busting (Thrombolytic) drugs. The results are poor for patients with large occulsive clots and who are at risk of bleeding, and extremely expensive for healthcare providers.
Vetex Medical is an early stage medical device based in Ireland that has developed a platform technology that rapidly removes high volumes of clot form the deep veins without the use of thrombolytic drugs, and so will radically challenge the inefficiencies and economics present in the current management of deep vein thrombosis.
Deep Vein Thrombosis in the larger veins of the upper limb represents $600m market opportunity. Interventions in the treatment of DVT have been increasing steadily over the last number of years with growth rates of 15%. This market segment is increasingly ‘on trend’ and set to witness expedited growth over the coming years.
Vetex Medical is ambitious in its’ plan to bring the FreeFlow technology to market in both Europe and the US in 2021, through completion of a Clinical Trial and through securing regulatory approvals to allow market entry. The Vetex Medical Team has the skills and experience to develop and commercialise this novel medical technology and to implement a high
growth strategy.
Wissenschaftliches Gebiet
Programm/Programme
Thema/Themen
Aufforderung zur Vorschlagseinreichung
Andere Projekte für diesen Aufruf anzeigenUnterauftrag
H2020-SMEInst-2018-2020-2
Finanzierungsplan
SME-2 - SME instrument phase 2Koordinator
H91 FC85 GALWAY
Irland
Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen).